X
Search
X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

Early Use of J&J’s Zytiga Extends Prostate Cancer Survival

Adding Johnson & Johnson’s Zytiga to standard hormone therapy reduced by nearly 40 percent the chance of death for men newly diagnosed with high-risk prostate cancer that had spread to other parts of the body, according to new trial results.

Read more. 

source: Reuters